Hims & Hers remains a compelling long-term play, with a resilient subscription-driven model, 85%+ retention, and 2.4 million ...

Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...

Hims & Hers Health (HIMS -1.19%) is a telehealth company that offers personalized solutions for its customers. And demand has been robust, with subscriptions for its products risi ...

Hims & Hers Health (NASDAQ: HIMS) experienced a sharp 35% drop in its stock price on June 23, 2025, following Novo Nordisk’s abrupt cancellation of their short-lived partnership. This steep ...

Initially, Hims & Hers rallied by over 100% starting in April 2025 on news that Novo Nordisk would adopt them as one of their weight loss drug providers and carriers.

Hims & Hers Health (NYSE: HIMS), a telehealth platform, recently released its Q1 financial results, revealing significant year-over-year growth. The company reported adjusted earnings per share of ...

Hims & Hers names Amazon veteran as COO Nader Kabbani, who led the technology giant’s acquisition of PillPack and the launch of Amazon Pharmacy, will take the role at the telehealth firm this month.

Fortune’s Jason Del Rey breaks down Prime Day’s biggest winners, surprises, and what the sales reveal about Amazon’s ...

Hims & Hers shares were trading at $44.55 on Monday. Hims also sells liraglutide, a generic version of another older Novo diabetes drug that causes weight loss, as well as Eli Lilly's rival Zepbound.

Hims & Hers stock plunged nearly 35% on Monday following Novo Nordisk's announcement. This steep sell-off indicates how much the termination of the Wegovy deal could impact Hims & Hers.